The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.00
Bid: 97.00
Ask: 98.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.031%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 98.00
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Shareholding/Share Incentive Plan

1 Sep 2021 07:00

RNS Number : 3003K
Diaceutics PLC
01 September 2021
 

 

1 September 2021

 

Diaceutics PLC

("Diaceutics" or "the Company")

 

PDMR Shareholding/Share Incentive Plan

 

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing has been notified that on 27 August 2021 Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Susanne Munksted and Damian Thornton (both PDMRs), in respect of their purchase of Shares pursuant to the Company's Global Share Incentive Plan ("Global SIP Scheme") for international employees. These purchases will be made each month until further notice.

 

In accordance with the SIP Scheme, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 2:1.

 

 

Enquiries:

 

Diaceutics PLC 

 

Philip White, Chief Financial Officer 

Via Alma PR 

 

 

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison

 

Stewart Wallace

 

Nick Adams

 

 

 

Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde

diaceutics@almapr.co.uk

Robyn Fisher

 

Kieran Breheny

 

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Susanne Munksted

2

Reason for notification

a.

Position/Status

Managing Director and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

113.00 p

126

Conditional share award:

Price(s)

Volume(s)

Nil

252

e.

Date of the transaction

Share purchase and Conditional share award: 27 August 2021

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Conditional share award: Off-Market

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Damian Thornton

2

Reason for notification

a.

Position/Status

Chief Operating Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares to matched by the grant of nil cost options over Shares under the Global Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

113.00 p

130

Options:

Price(s)

Volume(s)

Nil

260

 

 

e.

Date of the transaction

Share purchase and Option award: 27 August 2021

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Option award: Off-Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKDBQFBKDPFN
Date   Source Headline
7th Sep 202011:00 amRNSPrice Monitoring Extension
7th Sep 20207:00 amRNSHalf-year Report
27th Aug 20207:00 amRNSNotice of Results
22nd Jul 20207:00 amRNSNew contract win for DXRX platform
9th Jul 20207:00 amRNSHolding(s) in Company
8th Jul 20207:00 amRNSTrading update
6th Jul 20204:41 pmRNSSecond Price Monitoring Extn
6th Jul 20204:36 pmRNSPrice Monitoring Extension
3rd Jul 202010:43 amRNSHolding(s) in Company
3rd Jul 20207:00 amRNSIssue of Share Options
29th Jun 20202:55 pmRNSResult of General Meeting
19th Jun 20207:00 amRNSHolding(s) in Company
11th Jun 20202:00 pmRNSExercise of warrant
11th Jun 20207:00 amRNSPlacing of £20.5 million
19th May 20202:29 pmRNSResult of AGM
19th May 20207:00 amRNSAGM Statement
18th May 20207:00 amRNSDiagnostic network for precision medicine update
5th May 202011:22 amRNSDirector’s Shareholding - PCA Dealing
29th Apr 20207:00 amRNSCancer testing & diagnosis suffers sharp downturn
23rd Apr 20207:00 amRNSPosting of Annual Report and Notice of AGM
6th Apr 20207:00 amRNSIssue of Share Options
19th Mar 20207:00 amRNSBelfast investor presentation
17th Mar 20209:05 amRNSSecond Price Monitoring Extn
17th Mar 20209:00 amRNSPrice Monitoring Extension
16th Mar 202011:05 amRNSSecond Price Monitoring Extn
16th Mar 202011:00 amRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSFinal Results
12th Mar 20202:24 pmRNSPrivate investor briefing
27th Feb 20207:00 amRNSNotice of Results
17th Feb 20207:00 amRNSBelfast investor presentation
6th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
17th Jan 20202:53 pmRNSHolding(s) in Company
13th Jan 20209:05 amRNSSecond Price Monitoring Extn
13th Jan 20209:00 amRNSPrice Monitoring Extension
13th Jan 20207:00 amRNSYear-End Trading Update
25th Nov 20197:00 amRNSPresentation at AICon 2019
24th Oct 20197:00 amRNSPresentation at Big Data Belfast
21st Oct 20197:00 amRNSPharma Precision Medicine Readiness Report
10th Oct 20197:00 amRNSWorkshop presentation at EORTC
30th Sep 20198:01 amRNSPoster presentation at ESMO
23rd Sep 20197:00 amRNSDublin investor presentation
9th Sep 20197:00 amRNSHalf-year Report
8th Aug 20197:00 amRNSAppointment of Head of Global Data
8th Aug 20197:00 amRNSNotice of Results
8th Jul 20197:00 amRNSTrading update
17th Jun 20197:00 amRNSInvestment in data lake
28th May 20197:00 amRNSInvestor presentation
25th Mar 20194:29 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSHolding(s) in Company
21st Mar 20192:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.